CAH Quote, Financials, Valuation and Earnings

Cencora has a net margin of 0.8% compared to Cardinal Health's net margin of 0%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 157.14%.

Cardinal Health has a consensus price target of $129.74, signalling upside risk potential of 9.18%. On the other hand Cencora has an analysts' consensus of $266.34 which suggests that it could grow by 17.05%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.611, which suggesting that the stock is 38.904% less volatile than S&P 500. In comparison Cencora has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.467%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.69%. Cencora offers a yield of 0.91% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are smaller than Cencora quarterly revenues of $79.1B. Cardinal Health's net income of $416M is higher than Cencora's net income of $3.4M. Notably, Cardinal Health's price-to-earnings ratio is 23.12x while Cencora's PE ratio is 30.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.13x versus 0.16x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 0.8% compared to Cardinal Health's net margin of 8.28%. Cardinal Health's return on equity of -- beat Globus Medical's return on equity of 2.27%.

Cardinal Health has a consensus price target of $129.74, signalling upside risk potential of 9.18%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 12.89%. Given that Globus Medical has higher upside potential than Cardinal Health, analysts believe Globus Medical is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.611, which suggesting that the stock is 38.904% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.69%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are larger than Globus Medical quarterly revenues of $625.7M. Cardinal Health's net income of $416M is higher than Globus Medical's net income of $51.8M. Notably, Cardinal Health's price-to-earnings ratio is 23.12x while Globus Medical's PE ratio is 124.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.13x versus 4.62x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.8% compared to Cardinal Health's net margin of 0.26%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $129.74, signalling upside risk potential of 9.18%. On the other hand McKesson has an analysts' consensus of $653.95 which suggests that it could grow by 12.92%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.611, which suggesting that the stock is 38.904% less volatile than S&P 500. In comparison McKesson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 51.023%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.69%. McKesson offers a yield of 0.46% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are smaller than McKesson quarterly revenues of $93.7B. Cardinal Health's net income of $416M is higher than McKesson's net income of $241M. Notably, Cardinal Health's price-to-earnings ratio is 23.12x while McKesson's PE ratio is 29.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.13x versus 0.23x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0.8% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Pineapple's return on equity of --.

Cardinal Health has a consensus price target of $129.74, signalling upside risk potential of 9.18%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Pineapple, analysts believe Cardinal Health is more attractive than Pineapple.

Cardinal Health has a beta of 0.611, which suggesting that the stock is 38.904% less volatile than S&P 500. In comparison Pineapple has a beta of 28.578, suggesting its more volatile than the S&P 500 by 2757.84%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.69%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are larger than Pineapple quarterly revenues of --. Cardinal Health's net income of $416M is higher than Pineapple's net income of --. Notably, Cardinal Health's price-to-earnings ratio is 23.12x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.13x versus 70.72x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.